Overview
Selank is a synthetic heptapeptide based on the endogenous tetrapeptide tuftsin, modified with additional residues to improve stability. It was developed by Russian research institutes as an investigational anxiolytic and nootropic peptide. Research interest centers on its reported ability to influence anxiety-related behavior and cognition without the sedation or dependence associated with conventional anxiolytics, though human evidence is concentrated in studies from its country of origin.
Mechanism of action
Selank is proposed to modulate the balance of monoamine neurotransmitters and to influence GABAergic signaling, contributing to its reported anxiolytic profile. Research also describes effects on the expression of brain-derived neurotrophic factor (BDNF) and on enkephalin-degrading enzyme activity, which may prolong endogenous regulatory peptide signaling. As a tuftsin analog, it additionally exhibits immunomodulatory activity in laboratory studies. Exact receptor-level mechanisms are not fully defined.
Research findings
Russian clinical studies have reported anxiolytic effects comparable to certain conventional agents without notable sedation in study settings.,Animal research suggests modulation of serotonergic and other monoamine systems.,Laboratory work reports influence on BDNF expression and on enzymes that degrade regulatory peptides.,As a tuftsin derivative, immunomodulatory effects have been observed in research models.,Independent, large-scale clinical replication outside Russia is limited.
Research context
Selank has a short plasma half-life, and research formulations are frequently intranasal to study central nervous system exposure; precise human pharmacokinetics remain not well characterized. Study durations in the published literature have ranged from single-exposure behavioral studies to multi-week protocols, with endpoints focused on anxiety and cognitive measures and on biomarkers such as BDNF. This is a research reference only. Not approved for human use outside regulated settings; consult the primary literature.
Handling & storage
Lyophilized powder is generally stored frozen and protected from light and moisture under controlled laboratory conditions. Reconstituted solutions are typically refrigerated and used within a limited window per standard peptide laboratory handling, avoiding repeated freeze-thaw cycles.
Reported safety signals
Reported tolerability in available studies has generally been described as favorable, with a profile noted as lacking the sedation and dependence of conventional anxiolytics; comprehensive independent safety data are limited.
Studied alongside
Selank is frequently discussed alongside Semax, another Russian-developed neuropeptide, in cognitive and mood research; it is also referenced in sleep and stress contexts with compounds such as DSIP.
At a glance
Research strengths
- Defined synthetic sequence with improved stability over native tuftsin
- Reported anxiolytic profile without notable sedation in studies
- Multiple proposed mechanisms (monoaminergic, BDNF, immunomodulatory)
- Substantial body of Russian research literature
Limitations & cautions
- Clinical evidence concentrated in studies from its country of origin
- Limited independent international replication
- Pharmacokinetics in humans not well characterized
- Not an approved therapeutic outside investigational contexts
